Mercedes Benz has said it is selling 2 million Mercedes-Benz models with a DNA test to detect genetic disorders and diseases.
The company said it plans to offer the test in 2017 and 2018.
It’s the first time DNA testing has been offered to the general public, said David Tchichimana, head of corporate development at Mercedes Benz USA.
“We’re committed to the DNA test and its use in the future, so we are excited to introduce this important service to our customers,” he said.
In the past, Mercedes-benz.com has been a site that sold information about genetic disorders, including those related to the liver and heart.
This is the first major announcement about DNA testing for the brand, said Peter Ripp, a geneticist at the University of California, Berkeley.
DNA testing for genetic disorders was introduced to the U.S. in the mid-1990s and is now widespread in Europe, Australia and the United Kingdom.
More than 80 genetic diseases are linked to obesity, heart disease and cancers.
Genetic testing is currently offered through private health insurance companies and a small number of health insurers.
Genealogist Peter Hickey said there are genetic disorders that can be linked to certain diseases.
For example, he said it can be possible to have a genetic condition that causes a person to lose weight but then gain it again, which is known as obesity-associated metabolic syndrome.
If someone has this condition, the weight they are gaining could be the cause of their disease.
But genetics does not have a cure, he added.
Tchichimbana said the test will be available in a “large number” of Mercedes-brand models in 2019 and beyond.
Ripp said that in the U!
States, it is currently the only way to get DNA testing.
A new gene test will replace older models that will be phased out by 2020, he explained.
One issue that some geneticists worry about is the potential for the DNA in some older models to be lost, so DNA testing should not be relied on to identify diseases.
But he said DNA tests are currently in use by more than 300 million people in the United States, Canada and Europe.
There have been no reports of problems with older models.
However, the new test should not replace the need for genetic testing in general, said Hickey.
He said the cost of the test has been reduced by as much as 50 per cent in some cases.
Hickey also said that a number of other health insurance carriers have started offering DNA testing to their customers, including the Affordable Care Act health insurance exchanges.
Carbon nanotube testing, or CNT, has been used in other countries to identify rare diseases.